var data={"title":"Daratumumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Daratumumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791388?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=daratumumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Daratumumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665721\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Darzalex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48893480\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Darzalex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653232\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD38;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690698\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Premedicate approximately 1 to 3 hours prior to infusion with a corticosteroid, an oral antipyretic, and an oral or IV antihistamine (see Premedications below). Post-infusion, administer an oral corticosteroid to all patients to reduce the risk of delayed infusion reactions (see Post-infusion medications below). To prevent herpes zoster reactivation, initiate antiviral prophylaxis within 1 week after starting daratumumab and continue for 3 months following completion of treatment. Per the manufacturer, daratumumab dosing should be based on actual body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Multiple myeloma, relapsed/refractory:</b> Adults: IV: <b>Note: </b>Refer to specific protocol or to dexamethasone and lenalidomide, bortezomib, or pomalidomide monographs for dosing when used in combination with daratumumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 8: 16 mg/kg once weekly for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 9 to 24: 16 mg/kg once every 2 weeks for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 25 and beyond: 16 mg/kg once every 4 weeks until disease progression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with lenalidomide and low-dose dexamethasone (Dimopoulos 2016):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 8: 16 mg/kg once weekly for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 9 to 24: 16 mg/kg once every 2 weeks for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 25 and beyond: 16 mg/kg once every 4 weeks until disease progression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with pomalidomide and low-dose dexamethasone (Chari 2017):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 8: 16 mg/kg once weekly for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 9 to 24: 16 mg/kg once every 2 weeks for 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 25 and beyond: 16 mg/kg once every 4 weeks until disease progression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In combination with bortezomib and dexamethasone (Palumbo 2016):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 9: 16 mg/kg once weekly for 9 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 10 to 24: 16 mg/kg once every 3 weeks for 5 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 25 and beyond: 16 mg/kg once every 4 weeks until disease progression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose:</i> If a dose is missed, administer as soon as possible and adjust the schedule accordingly (maintain the treatment interval).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Premedications:</b> Administer 1 to 3 hours prior to each infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Corticosteroid:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Monotherapy:</i> Methylprednisolone 100 mg IV or equivalent intermediate- or long-acting corticosteroid; following the second infusion, the dose may be decreased (eg, methylprednisolone 60 mg [IV or oral] or equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination therapy:</i> Dexamethasone 20 mg prior to each infusion; administer IV prior to the first infusion; oral administration may be considered prior to subsequent infusions <b>plus</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Antipyretic:</i> Oral: Acetaminophen 650 to 1,000 mg <b>plus</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Antihistamine:</i> IV or Oral: Diphenhydramine 25 to 50 mg or equivalent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>The following premedication regimen has also been reported (Hofmeister 2016): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First infusion: Acetaminophen 325 mg orally, diphenhydramine 25 mg orally or IV, dexamethasone 20 mg IV, montelukast 10 mg orally, and famotidine 20 mg IV.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Subsequent infusions: Acetaminophen 325 mg orally, diphenhydramine 25 mg IV, and dexamethasone 20 mg IV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-infusion medication:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy: </i>Administer an oral intermediate- or long-acting corticosteroid (eg, methylprednisolone 20 mg or equivalent) on the first and second day after all infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy: </i>Consider administering low-dose oral methylprednisolone (20 mg or less) or equivalent on the first day after the infusion. If dexamethasone is administered the day after the infusion as part of combination chemotherapy, additional post-infusion corticosteroid therapy may not be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In patients with a history of chronic obstructive pulmonary disease, also consider short- and long-acting bronchodilators and inhaled corticosteroids post-infusion. If no major infusion reactions occur during the first 4 infusions, these additional inhaled post-infusion medications may be discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690699\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690700\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">CrCl 15 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl between 15 to 89 mL/minute did not have any meaningful effect on daratumumab pharmacokinetics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690701\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild (total bilirubin 1 to 1.5 times ULN and any ALT) or moderate (total bilirubin 1.5 to 3 times ULN and any ALT) impairment: There are no dosage adjustments provided in the manufacturer's labeling, however, mild or moderate impairment did not have any meaningful effect on daratumumab pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (total bilirubin &gt;3 times ULN and any ALT): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690702\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Refer to specific protocol or to dexamethasone and lenalidomide, bortezomib, or pomalidomide monographs for dosing adjustment for toxicity when used in combination with daratumumab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity:</b> No dose reductions of daratumumab are recommended; delay of daratumumab infusion may be required to allow for neutrophil and/or platelet recovery. Supportive care with growth factors and/or platelet transfusions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Infusion reactions:</b> Immediately interrupt infusion for reaction of any severity. Manage symptoms as clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Grade 1 or 2 (mild to moderate) infusion reaction:</i> Once symptoms resolve, resume the infusion at no more than 50% of the rate at which the reaction occurred. If no further reactions are observed, may escalate the infusion rate as appropriate up to the maximum rate of 200 mL/hour (see Administration).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Grade 3 (severe) infusion reaction:</i> Once symptoms resolve, consider resuming the infusion at no more than 50% of the rate at which the reaction occurred. If no further reactions are observed, may escalate the infusion rate as appropriate (see Administration). If a grade 3 reaction recurs, repeat the steps above. Permanently discontinue if a grade 3 infusion reaction occurs for the third time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Grade 4 (life-threatening) infusion reaction:</i> Permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665722\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Darzalex: 100 mg/5 mL (5 mL); 400 mg/20 mL (20 mL) [contains mouse (murine) and/or hamster protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45691983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690704\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV infusion only. Do not administer IV push or as a bolus. Premedicate with a corticosteroid, acetaminophen, and an IV or oral antihistamine (see Dosing) approximately 1 to 3 hours prior to administration. Infuse in an environment equipped to monitor for and manage infusion reactions. Administer with an infusion set fitted with a flow regulator and with an inline, sterile, non-pyrogenic, low protein-binding polyethersulfone filter (0.22 or 0.2 micrometer). Polyurethane, polybutadiene, polyvinylchloride, polypropylene, or polyethylene administration sets are required. Do not mix with or infuse with other medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Do not exceed infusion rates below. Begin infusion immediately after infusion bag reaches room temperature (if refrigerated). Infusion should be completed within 15 hours. Interrupt infusion for any severity of infusion reaction; if the reaction resolves, may resume infusion (see Dosage Adjustment for Toxicity). If infusion cannot be completed, do not save unused portion for reuse. Post-infusion, administer an oral corticosteroid to all patients to reduce the risk of delayed infusion reactions (see Dosing). In patients with a history of obstructive pulmonary disorder, consider short- and long-acting bronchodilators and inhaled corticosteroids post-infusion.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Infusion rate:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>First infusion (1,000 mL volume):</i> Infuse at 50 mL/hour for the first hour. If no infusion reactions occur, may increase the rate by 50 mL/hour every hour (maximum rate: 200 mL/hour).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Second infusion (500 mL volume):</i> Use a dilution volume of 500 mL only if there were no grade 1 or greater infusion reactions during the first 3 hours of the first infusion. Otherwise, continue to use a dilution volume of 1,000 mL and instructions for the first infusion. Infuse at 50 mL/hour for the first hour. If no infusion reactions occur, may increase the rate by 50 mL/hour every hour (maximum rate: 200 mL/hour).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Subsequent infusions (500 mL volume):</i> Use a modified initial rate for subsequent infusions (ie, third infusion onwards) only if there were no grade 1 or greater infusion reactions during a final infusion rate of &ge;100 mL/hour in the first 2 infusions. Otherwise, continue to use instructions for the second infusion. Infuse at 100 mL/hour for the first hour. If no infusion reactions occur, may increase the rate by 50 mL/hour every hour (maximum rate: 200 mL/hour).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653234\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple myeloma, relapsed/refractory:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of multiple myeloma (in combination with dexamethasone and either lenalidomide or bortezomib) in patients who have received at least one prior therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of multiple myeloma (in combination with dexamethasone and pomalidomide) in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of multiple myeloma (as monotherapy) in patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent or who are double refractory to a proteasome inhibitor and an immunomodulatory agent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690682\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Daratumumab may be confused with denosumab, dinutuximab, olaratumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45701090\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (39%), headache (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (27%), diarrhea (16%), constipation (15%), decreased appetite (15%), vomiting (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (72%; grade: 3: 30%; grade 4: 10%), neutropenia (60%; grade 3: 17%; grade 4: 3%), thrombocytopenia (48%; grade 3: 10%; grade 4: 8%), anemia (45%; grade 3: 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (23%), arthralgia (17%), limb pain (15%), musculoskeletal chest pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (21%), upper respiratory tract infection (20%), nasal congestion (17%), dyspnea (15%), nasopharyngitis (15%), pneumonia (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (48%), fever (3% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Physical health deterioration (3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653235\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to daratumumab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690685\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Daratumumab may increase neutropenia and thrombocytopenia when used in combination with other chemotherapy agents for the treatment of multiple myeloma. Lymphopenia, neutropenia, thrombocytopenia, and anemia (including grade 3 and 4 toxicity) were commonly reported as treatment emergent adverse reactions in clinical trials. Monitor for signs/symptoms of infection and bleeding. Monitor complete blood counts periodically; may require delay of daratumumab infusion to allow for neutrophil and/or platelet recovery. Supportive care with growth factors and/or platelet transfusions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Severe infusion reactions may occur (including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema, and pulmonary edema), mostly during the first infusion. Signs and symptoms include cough, throat irritation, and nasal congestion, as well as chills, vomiting, and nausea. Less commonly reported symptoms include wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension. Infusion reactions were reported in approximately 50% of patients in clinical trials. Reactions may also be seen during subsequent infusions, and generally occur either during the infusion or within 4 hours of completion; some reactions occurred up to 48 hours after the infusion. Premedication with antihistamines, antipyretics, and corticosteroids is required; interrupt infusion for any reaction and manage as appropriate. Reduce the infusion rate for grade 1, 2, or 3 reaction; permanently discontinue therapy for grade 4 infusion reaction. Administer in a facility with immediate access to resuscitative measures (eg, glucocorticoids, epinephrine, bronchodilators, and/or oxygen). Administer oral corticosteroids to all patients after daratumumab infusion to reduce the risk of delayed infusion reactions. Also consider short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interference with determination of myeloma response: Daratumumab (a human IgG kappa monoclonal antibody) may be detected on serum protein electrophoresis and immunofixation assays which monitor for endogenous M-protein. Interference with these assays by daratumumab may affect the determination of complete response and disease progression in some patients with IgG kappa myeloma protein.</p>\n    <p style=\"text-indent:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interference with serological testing: Through binding to CD38 on red blood cells, daratumumab use may result in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated Coombs test positivity may persist for up to 6 months after the last infusion. In addition, daratumumab (bound to red blood cells) masks antibody detection to minor antigens in the patient's serum; ABO and Rh blood type determination are not affected. Notify blood transfusion centers and blood banks that a patient has received daratumumab, and type and screen patients prior to therapy initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45693242\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45693239\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105443&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690683\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Daratumumab is a monoclonal antibody; monoclonal antibodies are known to cross the placenta. Based on the mechanism of action, daratumumab may cause myeloid or lymphoid cell depletion and decreased bone density in the fetus. Females of reproduction potential should use effective contraception during therapy and for 3 months after treatment is complete. The administration of live vaccines should be deferred for neonates and infants exposed to daratumumab in utero until a hematology evaluation can be completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690684\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if daratumumab is present in breast milk. Daratumumab is a monoclonal antibody; monoclonal antibodies can be detected in breast milk and are not expected to enter the neonatal or infant circulation in substantial amounts. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690706\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Complete blood cell counts periodically; type and screen (blood type) prior to initiating therapy; signs/symptoms of infusion reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690691\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Daratumumab is an IgG1&kappa; human monoclonal antibody directed against CD38. CD38 is a cell surface glycoprotein which is highly expressed on myeloma cells, yet is expressed at low levels on normal lymphoid and myeloid cells (Lokhorst 2015). By binding to CD38, daratumumab inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity, antibody dependent cell mediated cytotoxicity, and antibody dependent cellular phagocytosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45690693\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Central: Monotherapy: 4.7 &plusmn; 1.3 L; Combination therapy: 4.4 &plusmn; 1.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Monotherapy: 18 &plusmn; 9 days; Combination therapy: 23 &plusmn; 12 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105220\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Darzalex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $611.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/20 mL (20 mL): $2,447.23</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49189377\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Darzalex (AT, CZ, DE, DK, EE, FR, GB, HK, HR, IE, JP, LT, MY, NO, PT, RO, SG, SK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma [published online ahead of print July 21, 2017]. <i>Blood</i>. 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daratumumab-drug-information/abstract-text/28637662/pubmed\" target=\"_blank\" id=\"28637662\">28637662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Darzalex (daratumumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Darzalex (daratumumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(14):1319-1331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daratumumab-drug-information/abstract-text/27705267/pubmed\" target=\"_blank\" id=\"27705267\">27705267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hofmeister CC, Lonial S. How to integrate elotuzumab and daratumumab into therapy for multiple myeloma. <i>J Clin Oncol</i>. 2016;34(36):4421-4430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daratumumab-drug-information/abstract-text/27998219/pubmed\" target=\"_blank\" id=\"27998219\">27998219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>N Engl J Med</i>. 2015;373(13):1207-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daratumumab-drug-information/abstract-text/26308596/pubmed\" target=\"_blank\" id=\"26308596\">26308596</a>]</span><span class=\"doi\">10.1056/NEJMoa1506348</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(8):754-766.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daratumumab-drug-information/abstract-text/27557302/pubmed\" target=\"_blank\" id=\"27557302\">27557302</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105443 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45665721\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48893480\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45653232\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45690698\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45690699\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45690700\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45690701\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F45690702\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45665722\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45691983\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45690704\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45653234\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45690682\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45701090\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45653235\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45690685\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45693242\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45693239\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45690683\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45690684\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45690706\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45690691\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45690693\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46105220\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49189377\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105443|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=daratumumab-patient-drug-information\" class=\"drug drug_patient\">Daratumumab: Patient drug information</a></li></ul></div></div>","javascript":null}